Mechanistically, we demonstrated that the anti-cancer activity of NTP involves cytoskeletal rearrangements, resulting in changes in cellular morphology, as well as inhibition of the MMP-2/-9/uPA system and Akt/ERK signalings. The gene discussed is AKT1; the disease is cancer.